Table 3.
Primary and secondary outcomes (intention-to-treat population)*
| Nanocurcumin | Placebo | p-value | |
|---|---|---|---|
| Mean change from baseline (95% CI) | Mean change from baseline (95% CI) | ||
| ALSFRS-R (%) | –0.6 (–11.6 to 10.4) | –9.1 (–19.3 to 1.0) | 0.297 |
| Progression rate (%) | 2.3 (–29.3 to 34.0) | 36.8 (4.2 to 69.3) | 0.162 |
| MMT (%) | |||
| Total score | –17.0 (–21.2 to –12.9) | –19.3 (–23.6 to –15.1) | 0.470 |
| Upper limbs | –21.8 (–27.7 to –15.9) | –23.9 (–30.2 to –17.7) | 0.645 |
| Lower limbs | –4.5 (–37.9 to 28.8) | 6.1 (–27.7 to 39.8) | 0.674 |
| CMAP amplitude (%) | |||
| Median | –42.1 (–83.2 to –1.0) | –32.3 (–71.4 to 6.8) | 0.727 |
| Ulnar | –23.7 (–69.6 to 22.2) | –41.2 (–94.8 to 12.5) | 0.576 |
| Tibial | –30.1 (–56.3 to –3.9) | –31.7 (–56.6 to –6.9) | 0.922 |
| Common peroneal | –51.0 (–82.6 to –19.3) | –42.8 (–84.9 to –0.7) | 0.763 |
CI = confidence interval; ALSFRS-R = Revised Amyotrophic Lateral Sclerosis (ALS) Function Rating Scale; MMT = manual muscle testing; CMAP = compound muscle action potential
*Univariate general linear model with adjustment for the covariates was used for the analysis. Negative values mean deterioration except for the progression rate; positive values mean deterioration